Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.45 |
| ▸ | PGR | P06401 | 16/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15417475 | 0.90 | AR (0.36) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL12904805 | 0.87 | PDK1 (0.37) | ARPGRNR3C2 | |
| SCHEMBL13557241 | 0.86 | AR (0.47) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12904822 | 0.86 | AR (0.47) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12906882 | 0.86 | PGR (0.45) | ARPGRCYP19A1 | |
| SCHEMBL12904786 | 0.82 | PGR (0.64) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12904887 | 0.82 | PGR (0.64) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12904969 | 0.82 | PGR (0.64) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12904915 | 0.82 | PGR (0.64) | ARPGRNR3C2CYP19A1LMNA | |
| SCHEMBL12904978 | 0.82 | PGR (0.64) | ARPGRNR3C2CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623850-B2 | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623850-B2 | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | CYP19A1, NR5A1, SRD5A1 | AR 19/4885PGR 9/4885NR3C2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.